Description
FICONAX® is indicated in type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) that occurs with exogenous obesity, in whom primary and secondary failure is presented to caloric restriction and exercise and / or the administration of oral hypoglycemic agents.
FICONAX® is taken alone or in combination with sulfonylureas or other oral hypoglycemic agents, obtaining better glycemic control and improving lipid concentration in patients who respond poorly to control with diet or hypoglycemic agents alone.
Since the mechanism of action of FICONAX® does not stimulate the release of insulin from the beta cells of the pancreas, it can also be used in combination with the exogenous administration of insulin in those patients who do not respond to treatment with oral hypoglycemic agents. The use of the insulin-metformin combination has provided good glycemic control, reducing insulin requirements.
There are studies in which it has been proven that patients with polycystic ovarian disease, also known as polycystic ovary syndrome, have insulin resistance, which is why metformin has also been used as part of the treatment of this disease.
Reviews
There are no reviews yet.